Patent intelligence · US
US 9562039
Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both β2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activities
Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both β2 adrenergic receptor agonist and M3 muscarinic recepto…
Patent details — US 9562039
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 7, 2017
- Expiration
- Feb 2, 2037
- Applicant
- Almirall, S.A.
- Claims
- 11
- CPC classes
- A61K, A61K31/4709, A61K45/06, A61K9/0073
Quick answer
US 9562039 (Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both β2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activities) is held by Almirall, S.A.. Status: granted. Granted Feb 7, 2017. Expires Feb 2, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Almirall, S.A.
- Grant date
- Expiration
- Claims
- 11
- CPC classes
- A61K, A61K31/4709, A61K45/06, A61K9/0073, A61K9/0075, A61P
More from Almirall, S.A.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 9562039?
US 9562039 (Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both β2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activities) is held by Almirall, S.A.. Status: granted. Granted Feb 7, 2017. Expires Feb 2, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9562039?
Almirall, S.A. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 9562039 expire?
Our index shows an expiration date of Feb 2, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.